Tisztelt látogatónk!

Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)

No. 596/2014 on market abuse, as amended

(Market Abuse Regulation - MAR)

Dermapharm Holding SE raises EBITDA forecast for the full year 2021

Grünwald, December 16, 2021 - The Management Board of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) analysed the business development in November on the basis of the preliminary figures in its Management Board meeting today and decided to adjust the forecast for the financial year 2021. Accordingly, the Executive Board now expects Group EBITDA¹ to grow by 70 to 75 percent compared to the previous year (previously: 50 to 60 percent). In addition, the Executive Board confirms the revenue forecast for the 2021 financial year of 15 to 20 percent growth compared to the same period of the previous year.

¹ EBITDA is an alternative performance indicator that is not defined according to international accounting standards. The Company uses these metrics to allow for better comparability of the business over time and within the industry. EBITDA is defined as earnings before interest, taxes, depreciation and amortisation (see Dermapharm page 31, Annual Report 2020).

>End of the Ad hoc announcement<

Contact

Investor Relations & Corporate Communications

Britta Hamberger

Tel.: +49 (0)89 - 64186-233

Fax: +49 (0)89 - 64186-165

E-Mail: ir@dermapharm.com